| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥184.1B | ¥177.0B | +4.0% |
| Operating Income | ¥4.7B | ¥4.1B | +12.9% |
| Ordinary Income | ¥4.7B | ¥4.1B | +15.4% |
| Net Income | ¥-0.4B | ¥2.1B | -118.0% |
| ROE | -1.0% | 5.6% | - |
FY2026 Q3 cumulative results show Revenue of 18.4B yen (YoY +4.0%), Operating Income of 0.47B yen (YoY +12.9%), Ordinary Income of 0.47B yen (YoY +15.4%), and Net Income of -0.04B yen (YoY -118.0%). Revenue growth was modest at 4.0% driven by expansion across all three reporting segments, while operating profitability improved at a faster rate of 12.9% through operational leverage effects. However, net income turned negative primarily due to impairment losses of 371M yen recorded in the Pharmaceutical and Childcare Support segments during the period. The effective tax rate reached an abnormal 138%, compressing bottom-line results despite ordinary income growth. Total assets decreased to 13.0B yen from 13.3B yen while equity declined to 3.7B yen, reflecting the impact of current period losses on retained earnings.
Revenue increased 4.0% YoY to 18.4B yen, driven by balanced growth across core business segments. The Pharmaceutical segment contributed 7.40B yen in sales (up 3.2% YoY), the Childcare Support segment generated 7.57B yen (up 6.0% YoY), and the Nursing Care segment delivered 2.67B yen (down 0.5% YoY). Other segments including Food Business added 0.77B yen (up 8.8% YoY). Sales growth was broad-based with the Childcare Support segment showing the strongest momentum. On the profit side, gross profit reached 1.86B yen with a gross margin of 10.1%, indicating a low-margin business structure. Operating income improved 12.9% to 0.47B yen despite segment-level headwinds, as segment profit before allocation totaled 1.25B yen (up 8.7% YoY) while unallocated corporate expenses increased to 0.79B yen from 0.74B yen. The gap between operating income (0.47B yen) and net income (-0.04B yen) of approximately 0.51B yen is primarily explained by non-recurring impairment losses of 0.37B yen recorded against Pharmaceutical and Childcare Support segment assets. The impairment in Pharmaceutical segment totaled 20M yen in the prior period versus 371M yen in the current period, while Childcare Support recorded 199M yen in the prior period with no current disclosure, indicating asset quality adjustments. Interest expenses of 31M yen and an effective tax rate of 138% versus a normal rate further compressed net income. The performance pattern is revenue up/profit down at the net income level, though operating profit improved, indicating profitability pressure from one-time items and financial costs.
The Pharmaceutical segment generated revenue of 7.40B yen (up 3.2% YoY) with segment profit of 0.34B yen (down 15.6% YoY), yielding a segment margin of 4.5%. The Childcare Support segment is the largest core business with revenue of 7.57B yen (up 6.0% YoY) and segment profit of 0.82B yen (up 12.8% YoY), delivering the highest segment margin of 10.8%. The Nursing Care segment recorded revenue of 2.67B yen (down 0.5% YoY) with segment profit of 0.07B yen (up 547.6% YoY from 0.01B yen), showing a margin recovery to 2.5%. The Other segment (primarily Food Business) contributed revenue of 0.77B yen (up 8.8% YoY) with profit of 0.03B yen (up 73.9% YoY), at a margin of 4.0%. Material margin differences exist between segments, with Childcare Support demonstrating the strongest profitability at 10.8% compared to Pharmaceutical at 4.5% and Nursing Care at 2.5%. The Childcare Support segment's superior margins and growth trajectory position it as the earnings driver, while the Pharmaceutical segment faces margin compression despite revenue growth, exacerbated by current period impairment charges of 371M yen.
[Profitability] Operating margin of 2.5% improved from 2.3% YoY (up 0.2pt), while gross margin remained at approximately 10.1%, indicating a low-margin business model. Net profit margin turned negative at -0.2% from positive 1.2% YoY due to impairment losses. ROE deteriorated to -1.0% from positive 5.5% YoY, reflecting bottom-line losses. Asset turnover of 1.41 times demonstrates relatively efficient asset utilization above the company's historical levels. [Cash Quality] Cash and deposits stood at 1.78B yen against short-term debt of 0.80B yen, providing a coverage ratio of 2.2x for short-term borrowings. However, total current liabilities of 6.11B yen exceed current assets of 5.78B yen. [Investment Efficiency] Total asset turnover of 1.41 times compares favorably to prior period levels. Inventory turnover days of approximately 93 days based on inventory of 0.47B yen. Receivables turnover days of approximately 55 days based on receivables of 2.75B yen. Payables turnover days of approximately 51 days based on payables of 2.56B yen. [Financial Health] Current ratio of 94.6% indicates liquidity constraints with current assets insufficient to cover current liabilities. Debt-to-equity ratio of 2.55 times reflects elevated financial leverage, with interest-bearing debt of 2.33B yen against equity of 3.67B yen. Interest coverage ratio of 15.2 times (operating income 0.47B yen divided by interest expense 0.031B yen) indicates adequate earnings coverage of interest obligations despite leverage.
Cash and deposits decreased to 1.78B yen from 1.93B yen YoY, reflecting net cash outflow of 0.15B yen. Operating profit generation of 0.47B yen contributed to cash accumulation, though this was offset by the net loss of 0.04B yen after impairment charges and tax effects. Working capital showed a deficit position of -0.33B yen (current liabilities exceeding current assets), indicating tight liquidity management. Short-term borrowings decreased substantially by 0.40B yen (from 1.20B yen to 0.80B yen YoY, down 33.3%), suggesting debt reduction or refinancing activity. Total assets declined 2.0% to 13.0B yen with fixed assets decreasing, consistent with impairment charges recorded in the period. The combination of reduced short-term debt and lower cash levels indicates cash deployment toward debt reduction. Accounts receivable of 2.75B yen and inventory of 0.47B yen constitute working capital assets, while accounts payable of 2.56B yen provides supplier credit utilization. The current ratio of 94.6% warrants monitoring as it indicates potential short-term liquidity pressure, though cash coverage of short-term borrowings at 2.2x provides some buffer for immediate debt obligations.
Ordinary income of 0.47B yen approximates operating income of 0.47B yen, indicating minimal non-operating impact at the ordinary profit level. Non-operating income totaled 0.08B yen while non-operating expenses were 0.077B yen, resulting in a small net non-operating contribution. Interest and dividend income contributed positively while interest expenses of 0.031B yen represented the primary financial cost. The significant divergence between ordinary income of 0.47B yen and net income of -0.04B yen stems from extraordinary losses of 0.37B yen in impairment charges recorded in the Pharmaceutical segment, representing a non-recurring factor. These impairment losses equate to approximately 2.0% of revenue, materially impacting earnings quality for the period. The effective tax rate of 138% appears anomalous and likely reflects the interaction of pre-tax income of 0.10B yen with tax effects and deferred tax adjustments, resulting in tax expense exceeding pre-tax income. While operating cash flow data is not disclosed for the quarterly period, operating profit generation of 0.47B yen against net loss of 0.04B yen indicates that core business operations remain cash-generative before one-time charges, though earnings quality is compromised by the magnitude of asset impairments and tax burden abnormalities.
Full-year guidance projects Revenue of 24.6B yen (YoY +3.2%), Operating Income of 0.64B yen (YoY -0.2%), Ordinary Income of 0.63B yen (YoY -2.3%), and Net Income of 0.25B yen with EPS of 89.42 yen. Dividend forecast is 17 yen per share. Against these targets, Q3 cumulative progress rates are Revenue 74.8%, Operating Income 72.8%, Ordinary Income 74.5%, and Net Income at negative territory. Revenue progress of 74.8% is slightly below the standard Q3 benchmark of 75%, suggesting modest shortfall risk though within reasonable variance. Operating income progress of 72.8% indicates 27.2% of full-year target must be achieved in Q4, representing 0.17B yen quarterly requirement versus Q3 cumulative of 0.47B yen over nine months (average 0.052B yen per quarter), implying Q4 must deliver approximately 3.2x the quarterly average to meet guidance. Net income guidance of 0.25B yen versus cumulative loss of 0.04B yen requires Q4 net income of 0.29B yen, a challenging target given Q1-Q3 included 0.37B yen impairment charges. The guidance assumes no further material impairments in Q4 and normalization of tax effects. YoY changes embedded in guidance show revenue growth of 3.2%, operating income decline of 0.2%, and ordinary income decline of 2.3%, indicating conservative profit expectations despite sales growth, likely reflecting margin pressure and elevated corporate expenses.
The company paid an interim dividend of 13 yen per share and forecasts a year-end dividend of 17 yen per share, totaling 30 yen for the full year. Based on cumulative net income of -0.04B yen (net loss of 38M yen), the dividend payout ratio is negative at the current period level. However, the company maintains its dividend policy based on full-year earnings guidance of 0.25B yen net income, which would imply a payout ratio of approximately 34% if full-year targets are achieved (30 yen dividend per share against forecasted EPS of 89.42 yen). The divergence between current period losses and dividend maintenance suggests management confidence in Q4 recovery and commitment to shareholder returns. No share buyback activities are disclosed for the period. The sustainability of the 30 yen dividend depends critically on achieving the full-year net income target of 0.25B yen, as current cumulative losses and limited free cash flow visibility create uncertainty around dividend coverage from earnings and cash generation.
Asset impairment risk remains elevated, with 0.37B yen in impairments recorded in Q3 cumulative period concentrated in Pharmaceutical segment assets (371M yen), indicating potential ongoing challenges in asset recoverability and business unit profitability. Further impairments could materially impact full-year net income targets and strain equity capital. Liquidity and working capital risk is evidenced by a current ratio of 94.6% below the critical 1.0x threshold, with current liabilities of 6.11B yen exceeding current assets of 5.78B yen by 0.33B yen. While cash coverage of short-term borrowings is adequate at 2.2x, the overall liquidity position requires careful management of payables, receivables collection, and refinancing of maturing obligations. Low gross margin structure of 10.1% creates limited buffer for absorbing cost increases or competitive pricing pressure, particularly in the context of elevated SG&A expenses representing approximately 75.7% of revenue (13.92B yen SG&A against 18.4B yen sales), leaving operating margin at only 2.5%. Any deterioration in gross margin or increase in fixed costs would quickly erode operating profitability and threaten the ability to achieve guidance targets.
[Industry Position] (Reference - Proprietary Analysis) The company operates in the retail industry with analysis based on Q3 2025 industry medians. Profitability metrics show the company's operating margin of 2.5% significantly underperforms the industry median of 3.9% (IQR: 1.2%-8.9%), positioning in the lower quartile of the peer group. Net profit margin of -0.2% for the current period compares unfavorably to the industry median of 2.2% (IQR: 0.2%-5.7%), though this is heavily influenced by one-time impairment charges. ROE of -1.0% substantially trails the industry median of 2.9% (IQR: 0.5%-7.4%) due to current period losses. Financial health indicators reveal the company's current ratio of 0.95x falls well below the industry median of 1.93x (IQR: 1.48x-2.73x), indicating relatively weak liquidity positioning within the sector. Financial leverage of 3.55x exceeds the industry median of 1.76x (IQR: 1.51-2.55), placing the company at the upper end of the leverage range and suggesting higher financial risk relative to peers. Efficiency metrics show asset turnover of 1.41x outperforms the industry median of 0.95 (IQR: 0.77-1.16), indicating superior asset utilization efficiency. Revenue growth of 4.0% YoY exceeds the industry median of 3.0% (IQR: -0.1%-9.2%), demonstrating competitive top-line performance. Receivables turnover of approximately 55 days compares to industry median of 30 days (IQR: 19-60 days), while payables turnover of approximately 51 days aligns with industry median of 59 days (IQR: 44-70 days). Overall, the company demonstrates strong revenue growth and asset efficiency relative to industry peers but faces challenges in profitability margins, liquidity position, and leverage levels compared to sector benchmarks. (Industry: Retail, n=16 companies, Comparison: FY2025-Q3, Source: Proprietary Analysis)
Revenue growth momentum of 4.0% YoY exceeds industry median performance and reflects successful execution in the Childcare Support segment (up 6.0% YoY), which has emerged as the core profit driver with segment margins of 10.8% significantly above other divisions. This segment's contribution of 0.82B yen in profit (65% of total segment profit before allocation) demonstrates business model strength and positions it as the primary value creation engine warranting continued investment focus. Profitability structure reveals persistent margin compression challenges with gross margin at 10.1% and operating margin at 2.5% both below industry benchmarks, indicating limited pricing power and efficiency headroom. The combination of elevated SG&A expenses at 75.7% of revenue and corporate cost allocation of 0.79B yen constrains operating leverage, requiring strategic cost management initiatives to approach industry median operating margins. The divergence between operational performance (operating income up 12.9%) and reported net income (loss of 0.04B yen) is primarily attributable to non-recurring impairment charges of 0.37B yen in the Pharmaceutical segment, suggesting one-time asset quality adjustments rather than fundamental business deterioration, though recurrence risk warrants monitoring of asset recoverability assumptions and segment-level returns.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.